Pacira BioSciences
Develops non-opioid pain and musculoskeletal treatments built on a liposome drug-delivery platform.
Something off on this page? Send us feedback.
Profile
Sells non-opioid pain-management and musculoskeletal-health products to hospitals and outpatient surgery centers, led by EXPAREL, a long-acting local anesthetic built on an inherited liposome delivery technology. Revenue concentrates heavily in that single product, distributed through a small number of pharmaceutical wholesalers.
Develops non-opioid treatments for postsurgical pain and musculoskeletal conditions, sold mainly to hospitals and outpatient surgical centers rather than directly to patients. EXPAREL, a long-acting local anesthetic built on an inherited liposome drug-delivery technology, accounts for most revenue; ZILRETTA, an extended-release knee osteoarthritis injection, and iovera°, a cryoanalgesia device agreed for sale to another medical company, round out the portfolio.
Assembled through acquisition rather than built around a single founder, the business later added knee osteoarthritis and gene-therapy research. A recently enacted federal reimbursement rule now gives its non-opioid products separate payment status in outpatient settings.
Three national pharmaceutical wholesalers handle the large majority of distribution. Patent litigation over the lead product settled on terms deferring broad generic competition toward the end of the decade, while a gene-therapy candidate anchors the push beyond the founding product line.
Company facts
Categories
Key statistics
Year to date +5.3% · Average volume (30d) 620.9K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | Truist Financial | Target | $25 | $30 | ||
| Aug 5, 2026 | RBC Capital | Reiterate | Sector Perform | $25 | ||
| May 1, 2026 | Needham | Reiterate | Buy | $63 | $32 | |
| Dec 8, 2025 | Barclays | Target | $24 | $27 | ||
| Jan 30, 2025 | Truist Securities | Upgrade | Sell | Hold |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026Q2 FY26 | $0.65 | $0.73 | +13.0% | $191.1M | $192.4M | +0.7% | −9.96% |
| Apr 30, 2026Q1 FY26 | $0.61 | $0.60 | −1.6% | $171.8M | $177.4M | +3.2% | −4.12% |
| Feb 26, 2026Q4 FY25 | $0.85 | $0.57 | −32.9% | $200.3M | $196.9M | −1.7% | −3.01% |
| Nov 6, 2025Q3 FY25 | $0.65 | $0.70 | +7.7% | $201.9M | $179.5M | −11.1% | +4.50% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $168.9M | $181.1M | $179.5M | $196.9M | $177.4M | $192.4M | |
| Gross profit | $134.6M | $140.2M | $145.2M | $156.6M | $141.0M | $148.2M | |
| Operating income | $2.0M | $8.5M | $6.4M | $3.2M | $4.6M | $4.3M | |
| Net income | $4.8M | −$4.8M | $5.4M | $1.6M | $2.9M | $4.7M | |
| Diluted EPS | $0.10 | −$0.11 | $0.12 | $0.04 | $0.07 | $0.12 | |
| Gross margin | 79.7% | 77.4% | 80.9% | 79.5% | 79.5% | 77.0% | |
| Operating margin | 1.2% | 4.7% | 3.5% | 1.6% | 2.6% | 2.2% |
Fiscal years (4-quarter sums)FY21 $541.5M · FY22 $666.8M · FY23 $675.0M · FY24 $701.0M · FY25 $726.4M
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $251.0M · Total debt $412.1M · Total assets $1.24B · Shareholders' equity $672.0M
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 39.34M · Float 37.68M · 95.8% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 6.71M | 17.05% | 13F | Aug 7, 2026 |
| Pedro Escudero | 2.94M | 7.30% | 13D | Mar 12, 2026 |
| Doma Perpetual Capital Management LLC | 2.78M | 7.06% | 13F | Aug 12, 2026 |
| Vanguard Portfolio Management LLC | 2.41M | 6.12% | 13F | Aug 13, 2026 |
| Dimensional Fund Advisors LP | 2.10M | 5.35% | 13F | Aug 11, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 17, 2026 | Jonathan Slonin | officer: Chief Medical Officer | −3,040 | $23.23 |
| Jun 11, 2026 | Lauren Riker | officer: Senior Vice President, Finance | −6,115 | $23.50 |
| Jun 4, 2026 | Kristen Williams | officer: Chief Administrative Officer | −10,259 | $22.27 |
| Apr 23, 2026 | Shawn Cross | officer: Chief Financial Officer | −12,941 | $25.16 |
| Apr 20, 2026 | Shawn Cross | officer: Chief Financial Officer | −7,714 | $25.14 |
Peers
- Heron Therapeutics
Specialty biopharma in non-opioid postsurgical pain and antiemetic care
- Vertex Pharmaceuticals
Cystic fibrosis leader diversifying into non-opioid acute pain treatment
- Bioventus
Durham, NC medical device maker of hyaluronic acid knee OA injectables
- Anika Therapeutics
Hyaluronic acid viscosupplements rivaling non-opioid OA knee injectables
- Sanofi (ADR)
Global pharma marketing Synvisc-One, an HA rival to intra-articular OA therapy
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Pacira BioSciences | $25.76 | 0.00% | $1.01B | 73.3 | 8.3 | 1.4 | +6.2% |
| Heron Therapeutics | $0.3321 | +2.63% | $61.8M | — | — | 0.4 | +1.3% |
| Vertex Pharmaceuticals | $540.78 | −0.17% | $137.48B | 31.5 | 27.8 | 10.9 | +12.5% |
| Bioventus | $13.84 | −0.07% | $937.6M | 18.0 | 17.1 | 1.6 | +3.8% |
| Anika Therapeutics | $21.10 | −0.50% | $282.4M | — | 34.5 | 2.3 | +15.6% |
| Sanofi (ADR) | $44.83 | +0.02% | $107.62B | 78.9 | — | 1.9 | +11.2% |
| Median | 31.5 | 27.8 | 1.9 | +11.2% |